Filing Details
- Accession Number:
- 0000899243-19-004395
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2019-02-21 16:52:41
- Reporting Period:
- 2019-02-19
- Accepted Time:
- 2019-02-21 16:52:41
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1750019 | Tcr2 Therapeutics Inc. | TCRR | () | 4 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1134655 | Ansbert Gadicke | C/O Mpm Capital 450 Kendall Street Cambridge MA 02142 | Yes | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2019-02-19 | 79,644 | $0.00 | 79,644 | No | 4 | C | Indirect | See Footnote |
| Common Stock | Acquisiton | 2019-02-19 | 52,469 | $0.00 | 52,469 | No | 4 | C | Indirect | See Footnote |
| Common Stock | Acquisiton | 2019-02-19 | 146,447 | $0.00 | 146,447 | No | 4 | C | Indirect | See Footnote |
| Common Stock | Acquisiton | 2019-02-19 | 2,195,681 | $0.00 | 2,195,681 | No | 4 | C | Indirect | See Footnote |
| Common Stock | Acquisiton | 2019-02-19 | 351,155 | $0.00 | 351,155 | No | 4 | C | Indirect | See Footnote |
| Common Stock | Acquisiton | 2019-02-19 | 2,421,775 | $0.00 | 2,421,775 | No | 4 | C | Indirect | See Footnote |
| Common Stock | Acquisiton | 2019-02-19 | 9,291 | $0.00 | 88,935 | No | 4 | C | Indirect | See Footnote |
| Common Stock | Acquisiton | 2019-02-19 | 5,247 | $0.00 | 57,716 | No | 4 | C | Indirect | See Footnote |
| Common Stock | Acquisiton | 2019-02-19 | 17,085 | $0.00 | 163,532 | No | 4 | C | Indirect | See Footnote |
| Common Stock | Acquisiton | 2019-02-19 | 256,163 | $0.00 | 2,451,844 | No | 4 | C | Indirect | See Footnote |
| Common Stock | Acquisiton | 2019-02-19 | 35,115 | $0.00 | 386,270 | No | 4 | C | Indirect | See Footnote |
| Common Stock | Acquisiton | 2019-02-19 | 282,540 | $0.00 | 2,704,315 | No | 4 | C | Indirect | See Footnote |
| Common Stock | Acquisiton | 2019-02-19 | 1,373,333 | $15.00 | 1,569,235 | No | 4 | P | Indirect | See Footnote |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | C | Indirect | See Footnote |
| No | 4 | C | Indirect | See Footnote |
| No | 4 | C | Indirect | See Footnote |
| No | 4 | C | Indirect | See Footnote |
| No | 4 | C | Indirect | See Footnote |
| No | 4 | C | Indirect | See Footnote |
| No | 4 | C | Indirect | See Footnote |
| No | 4 | C | Indirect | See Footnote |
| No | 4 | C | Indirect | See Footnote |
| No | 4 | C | Indirect | See Footnote |
| No | 4 | C | Indirect | See Footnote |
| No | 4 | C | Indirect | See Footnote |
| No | 4 | P | Indirect | See Footnote |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Series A Preferred Stock | Disposition | 2019-02-19 | 493,306 | $0.00 | 79,644 | $0.00 |
| Common Stock | Series A Preferred Stock | Disposition | 2019-02-19 | 325,002 | $0.00 | 52,469 | $0.00 |
| Common Stock | Series A Preferred Stock | Disposition | 2019-02-19 | 907,073 | $0.00 | 146,447 | $0.00 |
| Common Stock | Series A Preferred Stock | Disposition | 2019-02-19 | 13,599,621 | $0.00 | 2,195,681 | $0.00 |
| Common Stock | Series A Preferred Stock | Disposition | 2019-02-19 | 2,174,998 | $0.00 | 351,155 | $0.00 |
| Common Stock | Series A Preferred Stock | Disposition | 2019-02-19 | 15,000,000 | $0.00 | 2,421,775 | $0.00 |
| Common Stock | Series B Preferred Stock | Disposition | 2019-02-19 | 57,552 | $0.00 | 9,291 | $0.00 |
| Common Stock | Series B Preferred Stock | Disposition | 2019-02-19 | 32,500 | $0.00 | 5,247 | $0.00 |
| Common Stock | Series B Preferred Stock | Disposition | 2019-02-19 | 105,825 | $0.00 | 17,085 | $0.00 |
| Common Stock | Series B Preferred Stock | Disposition | 2019-02-19 | 1,586,623 | $0.00 | 256,163 | $0.00 |
| Common Stock | Series B Preferred Stock | Disposition | 2019-02-19 | 217,500 | $0.00 | 35,115 | $0.00 |
| Common Stock | Series B Preferred Stock | Disposition | 2019-02-19 | 1,750,000 | $0.00 | 282,540 | $0.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect | ||
| 0 | No | 4 | C | Indirect |
Footnotes
- Each share of Series A Preferred Stock converted into shares of the Issuer's common stock, par value $0.0001 ("Common Stock"), on a 6.1938:1 basis upon the closing of the Issuer's initial public offering.
- The reported securities are owned directly by MPM Asset Management Investors BV2014 LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.
- The reported securities are owned directly by MPM Asset Management Investors SunStates Fund LLC. The Reporting Person disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.
- The reported securities are owned directly by MPM BioVentures 2014 (B), L.P. MPM BioVentures 2014 GP LLC is the general partner of MPM BioVentures 2014 (B), L.P. MPM BioVentures 2014 LLC is the managing member of MPM BioVentures 2014 GP LLC. The Reporting Person is a member of MPM BioVentures 2014 LLC and disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.
- The reported securities are owned directly by MPM BioVentures 2014, L.P. MPM BioVentures 2014 GP LLC is the general partner of MPM BioVentures 2014, L.P. MPM BioVentures 2014 LLC is the managing member of MPM BioVentures 2014 GP LLC. The Reporting Person is a member of MPM BioVentures 2014 LLC and disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.
- The reported securities are owned directly by MPM SunStates Fund, L.P. MPM SunStates Fund GP LLC is the general partner of MPM SunStates Fund, L.P. MPM SunStates GP Managing Member LLC is the managing member of MPM SunStates Fund GP LLC. The Reporting Person is a member of MPM SunStates Fund GP LLC and disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.
- The reported securities are held directly by UBS Oncology Impact Fund, L.P. The general partner of UBS Oncology Impact Fund, L.P. is Oncology Impact Fund (Cayman) Management L.P. The general partner of Oncology Impact Fund (Cayman) Management L.P. is MPM Oncology Impact Management LP. The general partner of MPM Oncology Impact Management LP is MPM Oncology Impact Management GP LLC. The Reporting Person is the managing director of MPM Oncology Impact Management GP LLC and disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.
- Each share of Series B Preferred Stock converted into shares of the Issuer's Common Stock on a 6.1938:1 basis upon the closing of the Issuer's initial public offering.
- The reported securities are owned directly by MPM Asset Management LLC. The Reporting Person is a member of MPM Asset Management LLC and disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.
Billionaire Hedge Funds
